Stent Thrombosis Patients with Hyporesponsiveness to Clopidogrel, Prasugrel, and Ticagrelor: A Case Series Using Short Thromboelastography
نویسندگان
چکیده
Patients after percutaneous coronary intervention (PCI) with stent implantation and functional hyporesponsiveness to P2Y12 inhibitors are at higher risk of ischaemic events, particularly stent thrombosis (ST). It is currently not routine practice to assess the functional response to these agents. However, concern over functional hyporesponsiveness to clopidogrel has led to widespread uptake of prasugrel and ticagrelor as the default P2Y12 inhibitor after stent implantation in patients with acute coronary syndrome. Here we report, for the first time, 3 cases in which patients who have had ST exhibit hyporesponsiveness to clopidogrel, prasugrel, and ticagrelor.
منابع مشابه
Stent Thrombosis Secondary to Ticagrelor Resistance as Demonstrated by Thromboelastography
Stent thrombosis is a dreaded complication of percutaneous coronary interventions (PCI). It is a prominent cause of mortality and major bleeding [1]. Antiplatelet therapy has played an important role in mitigating this adverse event, yet it is still a major complication. Clopidogrel, an irreversible P2Y12 inhibitor has been a mainstay of antiplatelet therapy for years. Clopidogrel’s nature as a...
متن کاملUse of prasugrel in a patient with clopidogrel hypersensitivity.
OBJECTIVE To report a case of successful use of prasugrel following percutaneous coronary intervention with placement of a bare metal stent in a patient with a documented hypersensitivity reaction to clopidogrel. CASE SUMMARY A 61-year-old male with a history of coronary artery disease with coronary stent placement presented with ST-elevation myocardial infarction. The patient had developed S...
متن کاملThe case for routine genotyping in dual-antiplatelet therapy.
Over 1 million coronary stent procedures are performed annually in the U.S., with dual-antiplatelet therapy, which includes the use of both aspirin and clopidogrel, being a cornerstone in the management of these patients after coronary intervention. Now, recent data have surfaced demonstrating altered active metabolite levels of clopidogrel in patients harboring hepatic cytochrome gene variants...
متن کاملEarly clinical outcomes as a function of use of newer oral P2Y12 inhibitors versus clopidogrel in the EUROMAX trial
Objective To ascertain whether different oral P2Y12 inhibitors might affect rates of acute stent thrombosis and 30-day outcomes after primary percutaneous coronary intervention (pPCI). Methods The European Ambulance Acute Coronary Syndrome Angiography (EUROMAX) randomised trial compared prehospital bivalirudin with heparin with optional glycoprotein IIb/IIIa inhibitor treatment in patients wi...
متن کاملATLANTIC: another reason to investigate the disconnect between stent thrombosis and mortality?
2015; 114: 7–8. Administration of a P2Y12-inhibitor is recommended by current guidelines in patients with acute coronary syndromes (ACS) (1). In clinical routine, this recommendation often results in pre-treatment with the respective P2Y12-inhibitor before the coronary anatomy is known. Two randomised trials from the clopidogrel era suggested that a significant reduction may be achieved with cl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
دوره 2016 شماره
صفحات -
تاریخ انتشار 2016